BioTuesdays

Long-time biotech analyst Doug Loe joins Leede Jones Gable

Doug Loe, Ph.D. has joined Leede Jones Gable as it continues to grow its capital markets team, boosting healthcare and biotechnology, and building on recent additions in sales and trading.

Dr. Loe, who brings more than two decades of senior capital markets experience in healthcare investment banking and research at Canadian investment houses, was named a managing director and analyst, healthcare and biotechnology. He is one of Canada’s pre-eminent healthcare and biotechnology analysts, recognized by both Starmine and Brendan Wood International.

Also joining Leede Jones is Michael Lorimer, who has raised billions of dollars in growth capital for promising companies and advised on numerous M&A mandates.

These new hires follow the recent arrival of Pat McCarthy, Sean Riley, Asha Khosla and Matt Green, who have all joined Leede Jones Gable Capital Markets this year.

In a statement, Jim Dale, CEO of Leede Jones, said the firm now has the critical mass to service its corporate clients. “With the new reality of life with Covid-19, we are all more focused on health and wellness,” he added.

Mr. Dale said this top-ranked healthcare team is known for finding great investment ideas in healthcare IT, biotechnology, specialty pharma, and med-tech. “It is a theme that is very timely and appealing to our retail and institutional clients.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.